Cytosorbents Corp(CTSO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 3 at 4:00 PM ET (Korea 11/4 06:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -5.8 | Insider Own | 13.98% | Shs Outstand | 3.1M | Perf Week | -6.39% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 84.74% | Insider Trans | 129.31% | Shs Float | 2.7M | Perf Month | 14.5% |
| Enterprise Value | 0.04B | PEG | - | EPS next Q | -0.9 | Inst Own | 24.53% | Short Float | 4.22% | Perf Quarter | -40.99% |
| Income | -0.02B | P/S | 0.38 | EPS this Y | -72.18% | Inst Trans | -1.03% | Short Ratio | 3.42 | Perf Half Y | -62.49% |
| Sales | 0.04B | P/B | - | EPS next 5Y | - | ROA | -42.38% | Short Interest | 0.11M | Perf YTD | -64.49% |
| Book/sh | -0.24 | P/C | 3.24 | EPS past 3/5Y | 44.07% 8.18% | ROE | -336.19% | 52W High | -73.29% ($17.00) | Perf Year | -70.92% |
| Cash/sh | 1.4 | P/FCF | - | Sales past 3/5Y | 2.23% -2% | ROIC | -130.68% | 52W Low | 59.85% ($2.84) | Perf 3Y | -84.01% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -61.01% | Gross Margin | 71.61% | Volatility(W/M) | 15.88% 16.59% | Perf 5Y | -96.29% |
| Dividend TTM | - | EV/Sales | 1.07 | Sales Y/Y TTM | 8.64% | Oper. Margin | -31.6% | ATR (14) | 0.71 | Perf 10Y | -95.72% |
| Dividend Ex-Date | - | Quick Ratio | 0.5 | EPS Q/Q | -342.6% | Profit Margin | -48.94% | RSI (14) | 48.45 | Recom | 2.5 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.66 | Sales Q/Q | 0.17% | SMA20 | 3.45% ($4.39) | Beta | 1.49 | Target Price | $34.83 |
| Payout | - | Debt/Eq | - | Earnings | 2026/11/12 | SMA50 | -12.25% ($5.17) | Rel Volume | 0.73 | Prev Close | $4.12 |
| Employees | 129 | LT Debt/Eq | - | EPS/Sales Surpr. | -55.56% 2.64% | SMA200 | -51.67% ($9.39) | Avg Volume(3M) | 0.03M | Price | $4.54 |
| IPO | 2006/8/8 | Option/Short | No/Yes | Trades | 816 | Volume | 24,325 | Change | 10.19% |
🩸 This company develops advanced medical devices that purify the blood of ICU and cardiac surgery patients outside the body. Its flagship product, CytoSorb, directly removes excess inflammatory substances and toxins from the blood, reducing the risk of organ failure and has been used in over 300,000 treatments worldwide. The company is also a blood purification specialist currently pursuing FDA approval for its antithrombotic removal device (DrugSorb-ATR).
Over the past 1 year, on the lower side
73% below its 1-year high.
Traded less than usual. That is 73% of its average volume.
Next earnings report: November 12
8 days to go.
CTSO has weak earnings and a weak balance sheet
Of every $100 in sales, $31.60 is lost.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -72.2% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $38. Peers typically go for $145.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -96.3%. The S&P 500 did +62% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 24.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #114 of 140 in the industry
Based on market cap of $14M.
LFWD#111 Lifeward Ltd $17M PER - 
HSCS#112 HeartSciences Inc $15M PER - 
PAVM#113 PAVmed Inc $15M PER - CTSO#114 Cytosorbents Corp $14M PER - 
SINT#115 SINTX Technologies Inc $13M PER - 
FAQ
What kind of company is CTSO?
CTSO belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of CTSO?
The market cap of CTSO is approximately $14M, ranking 5,319 within its sector.
What is the 52-week high and low for CTSO?
CTSO has recorded a 52-week high of $17.00 and a low of $2.84.
